Panelists discuss how challenges such as extended nursing workflow, patient hesitancy, limited formulation indications, reimbursement complexities, and insufficient economic incentives slow the ...
The US Food and Drug Administration (FDA) has approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) as a subcutaneous injection in adults, covering all approved indications ...
Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad category ...
PD-1 inhibitors belong to a class of medications known as immune checkpoint inhibitors, which have become an important part of many modern cancer treatment plans. PD-1 inhibitors work by helping the ...
The Chosun Ilbo on MSN
MSD's Keytruda subcutaneous form approved, marking 1-minute anticancer drug era
A subcutaneous (SC) form of immune anticancer drug that can be administered in 1 to 2 minutes by injection into the skin has ...
Subcutaneous Opdivo showed similar efficacy and safety to intravenous Opdivo in advanced ccRCC, with a slightly higher overall response rate. The CheckMate-67T trial confirmed pharmacokinetic and ...
Tecentriq Hybreza, a subcutaneous delivery of the drug, was approved for certain types of sarcoma, in addition to lung, skin and liver cancers. The Food and Drug Administration (FDA) approved ...
Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results